JP2015504871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504871A5 JP2015504871A5 JP2014547838A JP2014547838A JP2015504871A5 JP 2015504871 A5 JP2015504871 A5 JP 2015504871A5 JP 2014547838 A JP2014547838 A JP 2014547838A JP 2014547838 A JP2014547838 A JP 2014547838A JP 2015504871 A5 JP2015504871 A5 JP 2015504871A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nrf2 activator
- ppar gamma
- gamma agonist
- dimethyl fumarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 16
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 16
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 108010016731 PPAR gamma Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 102000000536 PPAR gamma Human genes 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 8
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 6
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical group COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 5
- 229960004419 dimethyl fumarate Drugs 0.000 claims 5
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 229960005095 pioglitazone Drugs 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- 229960004586 rosiglitazone Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000001530 fumaric acid Substances 0.000 claims 2
- -1 fumaric acid ester Chemical class 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11194292 | 2011-12-19 | ||
| EP11194292.6 | 2011-12-19 | ||
| EP12004652 | 2012-06-21 | ||
| EP12004652.9 | 2012-06-21 | ||
| US201261663761P | 2012-06-25 | 2012-06-25 | |
| US61/663,761 | 2012-06-25 | ||
| US13/654,632 US20130158077A1 (en) | 2011-12-19 | 2012-10-18 | Pharmaceutical compositions |
| US13/654,632 | 2012-10-18 | ||
| PCT/EP2012/074915 WO2013092269A1 (en) | 2011-12-19 | 2012-12-10 | Pharmaceutical compositions comprising glitazones and nrf2 activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504871A JP2015504871A (ja) | 2015-02-16 |
| JP2015504871A5 true JP2015504871A5 (enExample) | 2017-04-13 |
| JP6132850B2 JP6132850B2 (ja) | 2017-05-24 |
Family
ID=48610741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547838A Active JP6132850B2 (ja) | 2011-12-19 | 2012-12-10 | グリタゾンおよびｎｒｆ２アクチベーターを含む医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US20130158077A1 (enExample) |
| EP (1) | EP2793876B1 (enExample) |
| JP (1) | JP6132850B2 (enExample) |
| KR (2) | KR20220139414A (enExample) |
| CN (1) | CN103998035B (enExample) |
| AR (1) | AR089301A1 (enExample) |
| AU (4) | AU2012358420B9 (enExample) |
| BR (1) | BR112014014809A8 (enExample) |
| CA (1) | CA2859635C (enExample) |
| CL (1) | CL2014001639A1 (enExample) |
| EA (1) | EA201400729A1 (enExample) |
| ES (1) | ES2959111T3 (enExample) |
| HK (1) | HK1200711A1 (enExample) |
| IL (1) | IL233134A0 (enExample) |
| MX (2) | MX2014007254A (enExample) |
| PH (1) | PH12014501029A1 (enExample) |
| SG (1) | SG11201403241XA (enExample) |
| WO (1) | WO2013092269A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608196A (en) | 2008-08-19 | 2014-09-26 | Xenoport Inc | Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| EA201290808A1 (ru) | 2010-02-18 | 2013-03-29 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| EP2887934A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| MX2015007479A (es) * | 2012-12-11 | 2015-09-04 | Metabolic Solutions Dev Co Llc | Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas. |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| ES2955137T3 (es) | 2013-03-14 | 2023-11-28 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016071727A1 (en) | 2014-11-04 | 2016-05-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prevention and the treatment of rapidly progressive glomerulonephritis |
| WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| KR101704410B1 (ko) | 2015-07-22 | 2017-02-22 | 대구가톨릭대학교산학협력단 | 사파논 a를 함유하는 심혈관질환의 예방 및 치료용 조성물 |
| US20180318246A1 (en) * | 2015-10-28 | 2018-11-08 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| EP3411361B1 (en) * | 2016-02-03 | 2020-11-25 | Rigel Pharmaceuticals, Inc. | Nrf2 activating compounds and uses thereof |
| CN106389457A (zh) * | 2016-11-30 | 2017-02-15 | 胡立志 | PPAR‑γ激动剂在制备治疗脱发药物中的应用及治疗脱发的药物 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| CN108685903B (zh) * | 2018-07-05 | 2019-10-18 | 陕西师范大学 | 鼠尾草酚在制备防治实验性自身免疫性脑脊髓炎药物的应用 |
| WO2020094767A1 (en) | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| TW202038918A (zh) * | 2018-11-27 | 2020-11-01 | 日商協和麒麟股份有限公司 | 醫藥組合物 |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| CN111606828B (zh) * | 2019-02-22 | 2023-07-28 | 浙江海正药业股份有限公司 | (E)-α,β-不饱和酰胺化合物的晶型及其制备方法和用途 |
| CN109846867A (zh) * | 2019-03-29 | 2019-06-07 | 北京中医药大学 | 花姜酮用于制备抗心肌缺血的药物的用途 |
| GB2601667B (en) * | 2019-08-05 | 2023-01-25 | Ibm | Combination therapy to achieve enhanced antimicrobial activity |
| CN110279866B (zh) * | 2019-08-12 | 2021-06-29 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品 |
| CN110613712B (zh) * | 2019-10-22 | 2021-06-29 | 上海交通大学医学院附属第九人民医院 | 中药组合物及其在治疗血管炎症和内皮损伤中的应用 |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| CN113244221B (zh) * | 2020-02-12 | 2022-10-25 | 华东师范大学 | 双甲基鼠尾草酚在制备治疗恶病质疾病的药物中的应用 |
| WO2021173658A1 (en) * | 2020-02-24 | 2021-09-02 | Hofmann Robert F | Naphthoquinone-based chalcone derivatives and uses thereof |
| US20230134760A1 (en) * | 2020-03-04 | 2023-05-04 | Hongbing Wang | Car and nrf2 dual activator agents for cyclophosphamide-based and doxorubicin-based treatments of cancer |
| US20230099229A1 (en) * | 2020-03-13 | 2023-03-30 | Reprise Pharmaceuticals, Inc. | Methods of treating multiple sclerosis |
| CN111574437A (zh) * | 2020-06-22 | 2020-08-25 | 上海长车生物科技有限公司 | (e)-3-芳杂环基丙-2-烯酸衍生物及其制备和用途 |
| CN111529514A (zh) * | 2020-06-23 | 2020-08-14 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种特丁基对苯二酚的应用及治疗椎间盘退变的药物 |
| CA3195060A1 (en) * | 2020-09-14 | 2022-03-17 | Triterpenoid Therapeutics, Inc. | Analogs of cddo-2p-im and cddo-3p-im |
| WO2023158678A1 (en) * | 2022-02-15 | 2023-08-24 | Emory University | Fumaric acid esters, inhalation administration methods, pharmaceutical uses and compositions |
| KR20230123323A (ko) | 2022-02-16 | 2023-08-23 | 대구대학교 산학협력단 | 알릴 이소티오시아네이트(Allyl isothiocyanate)를 유효성분으로 포함하는 골 대사성 질환의 예방, 개선 또는 치료용 조성물 |
| CN114414809B (zh) * | 2022-03-28 | 2022-06-21 | 中元伯瑞生物科技(珠海横琴)有限公司 | 用于诊断尘肺病的生物标志物的应用 |
| WO2024047248A1 (en) | 2022-09-02 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| CN117137897B (zh) * | 2023-10-31 | 2024-02-13 | 中国中医科学院中药研究所 | 索法酮在制备用于预防/治疗银屑病的药物中的应用 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US807113A (en) | 1905-03-27 | 1905-12-12 | Frederick O Dyer | Puzzle. |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| JP4295458B2 (ja) | 1999-06-30 | 2009-07-15 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ活性調節用化合物 |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| US6403121B1 (en) | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| GB0021978D0 (en) * | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20040013643A1 (en) | 2000-09-19 | 2004-01-22 | Novlmmune S.A. | Methods for treatment of multiple sclerosis with statins |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| AU2002219236B2 (en) | 2001-01-12 | 2006-02-09 | Biogen International Gmbh | Fumaric acid amides |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| GB2373725A (en) | 2001-03-30 | 2002-10-02 | Novartis Ag | Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production |
| DE60236273D1 (de) * | 2001-05-03 | 2010-06-17 | Cornell Res Foundation Inc | Behandlung von krankheiten, die durch hpv verursacht werden |
| FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| AU2004208606B2 (en) | 2003-01-29 | 2009-09-24 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
| WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
| DE602004010531T2 (de) | 2003-09-09 | 2008-07-03 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
| DE10342423A1 (de) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20070086967A1 (en) | 2003-12-03 | 2007-04-19 | Brian Macdonald | Treatment of psoriasis with rosiglitazone |
| WO2005086904A2 (en) | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| WO2006004803A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| ITMI20041825A1 (it) | 2004-09-24 | 2004-12-24 | Medestea Res & Production Srl | Agonisti dei ricettori attivanti la proliferazione dei perossisomi, utili nella prevenzione o nel trattamento della gastrite |
| EP3470064A1 (en) | 2004-10-08 | 2019-04-17 | Fwp Ip Aps | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
| US20080004344A1 (en) | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
| DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| EP2186819A1 (en) | 2005-07-07 | 2010-05-19 | Aditech Pharma AG | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| EP1951206A1 (en) | 2005-10-07 | 2008-08-06 | Aditech Pharma AB | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| UA91729C2 (ru) | 2005-12-22 | 2010-08-25 | Такеда Фармасьютикал Компани Лимитед | Твердая форма лекарственного препарата |
| PL2019671T3 (pl) | 2006-05-05 | 2015-02-27 | Univ Michigan Regents | Związki pośrednie do wytwarzania dwuwartościowych mimetyków Smac |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| US20080103165A1 (en) | 2006-09-19 | 2008-05-01 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| LT2139467T (lt) | 2007-02-08 | 2016-10-10 | Biogen Ma Inc. | Neuroapsauga, sergant demielinizuojančia liga |
| PT2653873T (pt) | 2007-02-08 | 2022-07-26 | Biogen Ma Inc | Composições e utilizações para o tratamento de esclerose múltipla |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| CA2693628A1 (en) | 2007-07-11 | 2009-01-15 | Cardoz Ab | New combination for use in the treatment of imflammatory disorders |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| ME03529B (me) | 2008-01-11 | 2020-04-20 | Reata Pharmaceuticals Inc | Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti |
| EP2242747A1 (de) | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| DE102008030023A1 (de) | 2008-06-16 | 2009-12-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit |
| GB0913672D0 (en) | 2009-08-05 | 2009-09-16 | Argenta Discovery Ltd | Glitazones |
| NZ608196A (en) | 2008-08-19 | 2014-09-26 | Xenoport Inc | Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US20110190242A1 (en) * | 2008-09-23 | 2011-08-04 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
| US20100087481A1 (en) | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| HUE035013T2 (en) | 2009-02-13 | 2018-05-02 | Reata Pharmaceuticals Inc | Delayed release, oral dosage compositions that contain amorphous cddo-me |
| CN102427727A (zh) | 2009-04-29 | 2012-04-25 | 比奥根艾迪克Ma公司 | 神经变性和神经炎症的治疗 |
| WO2011039175A1 (en) * | 2009-09-29 | 2011-04-07 | Bodo Melnik | Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
| NZ600421A (en) | 2009-12-15 | 2014-06-27 | Metabolic Solutions Dev Co Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| HUE025878T2 (en) | 2010-02-12 | 2016-05-30 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
| WO2012040082A2 (en) | 2010-09-21 | 2012-03-29 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| US20140080795A1 (en) | 2010-11-19 | 2014-03-20 | University Of Rochester | NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction |
| CN102552140B (zh) * | 2011-01-12 | 2013-05-29 | 北京人福军威医药技术开发有限公司 | 罗格列酮的液体组合物 |
| US20140142095A1 (en) | 2011-04-28 | 2014-05-22 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| US20140308244A1 (en) | 2011-08-08 | 2014-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Combination Therapy for Treatment of Inflammatory Demyelinating Disease |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| BR112014026640B1 (pt) | 2012-04-27 | 2021-05-18 | Reata Pharmaceuticals, Inc | compostos derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimórficas, composição farmacêutica, e uso dos mesmos |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| BR112015018048A2 (pt) | 2013-01-30 | 2020-01-28 | Intekrin Therapeutics Inc | agonistas de ppary para tratamento de esclerose múltipla |
| EA201592020A1 (ru) | 2013-04-22 | 2016-05-31 | Кадила Хелзкэр Лимитед | Новая композиция для неалкогольной жировой болезни печени (нажбп) |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| DK3388064T3 (da) | 2014-04-02 | 2021-04-19 | Minoryx Therapeutics S L | 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet |
| WO2016074684A1 (en) | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
| SG10202102198RA (en) | 2016-09-13 | 2021-04-29 | Intekrin Therapeutics Inc | Treatment of multiple sclerosis with chs-131 |
| US11382889B2 (en) | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| EA202092953A1 (ru) | 2018-06-06 | 2021-04-12 | Минорикс Терапьютикс С.Л. | Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона |
| PL3801515T3 (pl) | 2018-06-06 | 2025-07-14 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych |
| BR112020024939A2 (pt) | 2018-06-06 | 2021-03-09 | Minoryx Therapeutics S.L. | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]benzil]-1,3-tiazolidina-2,4-diona e seus sais |
-
2012
- 2012-10-18 US US13/654,632 patent/US20130158077A1/en not_active Abandoned
- 2012-12-10 ES ES12801539T patent/ES2959111T3/es active Active
- 2012-12-10 SG SG11201403241XA patent/SG11201403241XA/en unknown
- 2012-12-10 KR KR1020227033805A patent/KR20220139414A/ko not_active Ceased
- 2012-12-10 EA EA201400729A patent/EA201400729A1/ru unknown
- 2012-12-10 CN CN201280062704.0A patent/CN103998035B/zh active Active
- 2012-12-10 BR BR112014014809A patent/BR112014014809A8/pt not_active Application Discontinuation
- 2012-12-10 PH PH1/2014/501029A patent/PH12014501029A1/en unknown
- 2012-12-10 HK HK15101190.9A patent/HK1200711A1/xx unknown
- 2012-12-10 AU AU2012358420A patent/AU2012358420B9/en active Active
- 2012-12-10 CA CA2859635A patent/CA2859635C/en active Active
- 2012-12-10 EP EP12801539.3A patent/EP2793876B1/en active Active
- 2012-12-10 MX MX2014007254A patent/MX2014007254A/es unknown
- 2012-12-10 MX MX2018012169A patent/MX394473B/es unknown
- 2012-12-10 WO PCT/EP2012/074915 patent/WO2013092269A1/en not_active Ceased
- 2012-12-10 KR KR1020147019944A patent/KR102188487B1/ko active Active
- 2012-12-10 JP JP2014547838A patent/JP6132850B2/ja active Active
- 2012-12-18 AR ARP120104793A patent/AR089301A1/es unknown
-
2013
- 2013-02-01 US US13/756,687 patent/US20130172391A1/en not_active Abandoned
-
2014
- 2014-06-15 IL IL233134A patent/IL233134A0/en unknown
- 2014-06-19 CL CL2014001639A patent/CL2014001639A1/es unknown
-
2016
- 2016-11-21 US US15/356,766 patent/US10426763B2/en active Active
-
2017
- 2017-09-05 AU AU2017225019A patent/AU2017225019B2/en active Active
-
2019
- 2019-06-25 AU AU2019204493A patent/AU2019204493B2/en active Active
- 2019-08-28 US US16/553,219 patent/US11484530B2/en active Active
-
2021
- 2021-03-03 AU AU2021201390A patent/AU2021201390B2/en active Active
-
2022
- 2022-10-26 US US18/049,652 patent/US12083107B2/en active Active
-
2024
- 2024-09-05 US US18/825,022 patent/US20240423967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504871A5 (enExample) | ||
| Mathews et al. | Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2012193216A5 (enExample) | ||
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2015038135A5 (enExample) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| JP2015500225A5 (enExample) | ||
| SG10201810154WA (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2016511753A5 (enExample) | ||
| JP2017505285A5 (enExample) | ||
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| WO2015171965A3 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| JP2017501140A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| JP2017512194A5 (enExample) | ||
| JP2016128399A5 (enExample) | ||
| IN2015DN00528A (enExample) | ||
| JP2017507142A5 (enExample) | ||
| JP2016515550A5 (enExample) |